Cancer genes

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials – we tell the story from discovery to translation.

We speak to Professor Shankar Balasubramanian about his work on NGS, his incredible translational journey and the power of the pub…

Using the technology, scientists have revealed that cell division isn’t necessarily the main cause of genetic changes in human tissue DNA.

Genetic changes in tumours could be used to predict who will benefit from immunotherapy, and who should receive other treatments. 

25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off.

New research reveals how some cancer cells double their genome to help them survive. Find out more about cancer’s ‘spare tyre’.

Research reveals how genetic variations in the regions of DNA that don’t code for proteins, once dismissed as ‘junk DNA’, can affect a person’s risk of cancer.

Potential new drug targets for an aggressive type of brain tumour have been uncovered in the lab, thanks to a ‘reverse engineering’ approach using DNA editing.

Our international team of scientists are tackling a fundamental question about how cancer develops: why do some gene faults only cause cancer in certain organs?

UK scientists are putting together a list of the most promising potential cancer drug targets in one of the largest lab studies of its kind.